For adults and children with hemophilia B
LONG-LASTING
BLEED PROTECTIONFOR THE EXPLORER WITHIN
ONLY IDELVION DELIVERS
Patients who started and stayed on prophylaxis prove IDELVION has powerful efficacy with both 7- and 14-day dosing*
EXPLORE IDELVIONEFFICACY
*Of the 23 subjects in Arm 2, 19 were transitioned from on-demand to 7-day prophylaxis. The median AsBR during prophylaxis treatment was 0.7 (range: 0 to 4.2). Data for Arms 1 and 2 based on matched-pairs design.
†Once well-controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
Resources for your patients through IDELVION ConnectSM
Over 95% of commercially insured patients paid $0 for IDELVION through the co-pay program in 2020.4
CSL Behring is committed to providing treatment and support services that make a meaningful difference in the lives of people with bleeding disorders.
Resources are available to help your eligible patients get the treatment they need for hemophilia B, including:
- A free trial of IDELVION
- Co-pay assistance‡
- Lapse-in-coverage support with the CSL Behring AssuranceSM program§
- Reimbursement and access support
References: 1. Data on file. Available from CSL Behring as DOF IDL-006. 2. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735. 3. Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016;127(14):1761-1769. doi:10.1182/blood-2015-09-669234. 4. Data on file. Available from CSL Behring as DOF IDL-009.
Have additional questions?
Connect with CSL Behring Medical Affairs to
find additional information and ask questions.